Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers with few diagnostic or prognostic biomarkers. This metabolomics study aimed to identify new serum prognostic biomarkers to improve the prediction of overall survival in patients with metastatic STS. The study enrolled 24 patients treated with the same trabectedin regimen. The baseline serum metabolomics profile, targeted to 68 metabolites encompassing amino acids and bile acids pathways, was quantified by liquid chromatography-tandem mass spectrometry. Correlations between individual metabolomics profiles and overall survival were examined and a risk model to predict survival was built by Cox multivariate regression. The median overall survival of the studied patients was 13.0 months (95% CI, 5.6–23.5). Among all the metabolites investigated, only citrulline and histidine correlated significantly with overall survival. The best Cox risk prediction model obtained integrating metabolomics and clinical data, included citrulline, hemoglobin and patients’ performance status score. It allowed to distinguish patients into a high-risk group with a low median overall survival of 2.1 months and a low- to moderate-risk group with a median overall survival of 19.1 months (p < 0.0001). The results of this metabolomics translation study indicate that citrulline, an amino acid belonging to the arginine metabolism, represents an important metabolic signature that may contribute to explain the high inter-patients overall survival variability of STS patients. The risk prediction model based on baseline serum citrulline, hemoglobin and performance status may represent a new prognostic tool for the early classification of patients with metastatic STS, according to their overall survival expectancy.
Mesoporous silica channels of different sizes are used to stabilize γ-Ga2O3:Cr3+ spinel nanocrystals with phase stability up to 1000 °C. Their optical properties are deeply investigated.
Study on the impact of silica nanoparticles on cancer cells using physicochemical and biomolecular characterization in different cell culture media to understand cellular responses.
The epidermal growth factor receptor inhibitor (EGFRIs) treatments are commonly associated with the development of adverse skin effects. This study aims to investigate the lipid composition change in sebum during cetuximab-based treatment in an attempt to identify specific metabolic signatures useful in predicting the occurrence of severe skin toxicity. Sebum from 30 metastatic colorectal cancer (mCRC) patients was collected at three time points during the targeted therapy by the application of Sebutape® on the forehead, and the major lipid classes were analyzed and quantified by 1H-NMR. Univariate analysis was performed to reveal significant alterations among patients in sebum production as well as lipid composition and over the course of cetuximab therapy. A transient but significant decrease in sebum production associated with a reduction in the relative content of triglycerides (TG) and squalene (SQ) was found to be induced by cetuximab administration. The reduction of these two lipid classes was also found to be associated with the severity of skin rash experienced by patients. The results of this study indicate that cetuximab-based treatment can reduce sebum gland activity, leading to an overall decrease in sebum production and the induction of specific modifications to its composition. The extent of the loss of skin barrier function may be important for determining the severity of skin toxicity development.
This review navigates the Nanoverse , an expanding dimension that connects emerging nanoscale materials with medicine, biosensing, and safety, highlighting how innovation, regulation, and ethics converge to guide nanotechnology for a better society.
Despite the clinical benefits associated with the use of continuous and flash glucose monitoring systems (GMS), they are frequently associated with dermatological adverse effects, most notably allergic contact dermatitis (ACD). Chemical analysis of devices is often the only means to confirm the presence of suspected sensitizers or detect emerging allergens in these products. Although previous research efforts lead to the identification of some main allergens such as acrylates and colophony compounds, new allergens continue to emerge and the presence of known allergens in devices cannot be excluded. However, no validated quantitative analytical methods for these compounds in GMS have been reported. A quantitative gas chromatography-mass spectrometry (GC-MS) method was developed and validated, with a focus on optimizing the extraction from the devices. An untargeted screening workflow was incorporated to detect additional potentially relevant allergens. Targeted analysis enabled quantification (14 compounds) or estimated abundance analysis determination (5 compounds) of relevant allergens. The method was applied to unused and used Dexcom G7 and associated adhesive patches. Different allergens were detected and quantified including isobornyl acrylate, methyl dehydroabietate, and isocyanates. Other compounds were only detected in used devices, such as cetyl alcohol, isopropyl palmitate and isopropyl myristate. The analysis revealed the presence of known and new allergens in medical devices for diabetes. Several allergens were present in unused devices, but others were detected only in used devices. These additional compounds likely accumulated from daily usage, leading to what we defined as the "sponge effect".